Nitrolingual (Glyceryl Trinitrate)

Glyceryl trinitrate acts as a nitric‑oxide donor. Once absorbed, it is converted to nitric oxide, which activates guanylate cyclase, raises cyclic GMP levels, and relaxes vascular smooth muscle. This results in dilation of coronary arteries and reduced cardiac workload, alleviating chest pain.

The specific dose of Nitrolingual is determined by the prescribing clinician based on the individual’s clinical condition, severity of angina, and response to therapy. The prescriber will select the appropriate tablet strength and frequency according to current practice guidelines.

The safety of Nitrolingual in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Nitrolingual, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nitrolingual (glyceryl trinitrate) belongs to the organic nitrate class, offering rapid sublingual onset for acute angina relief. Compared with beta‑blockers or calcium‑channel blockers, nitrates act directly on vascular smooth muscle to dilate coronary vessels, making them especially useful for immediate symptom control.

Nitrolingual tablets should be stored at ambient temperature, below 25 °C, in their original blister pack. Protect them from moisture, excessive heat, and direct sunlight to maintain potency and stability throughout their shelf life.

Nitrolingual is taken sublingually. The tablet is placed under the tongue and allowed to dissolve completely without swallowing. This route provides rapid absorption into the bloodstream, delivering quick relief of angina symptoms.

The most serious risks include severe hypotension, syncope (fainting), and rare cases of methemoglobinemia. Patients should be monitored for sudden drops in blood pressure and advised to seek medical attention if they experience fainting, chest pain that does not improve, or any signs of allergic reaction.

Nitrolingual should be avoided in patients with known hypersensitivity to glyceryl trinitrate or other organic nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe anemia, increased intracranial pressure, or uncontrolled hypotension.